Bill Snyder

From left, Huan Tao, MD, PhD, Sean Davies, PhD, Jiansheng Huang, PhD, and MacRae Linton, MD, led the study that identified a potential new treatment for atherosclerosis.

‘Scavenger’ molecule may point to new atherosclerosis treatment

A small-molecule “scavenger” that reduces inflammation and formation of atherosclerotic plaque in blood vessels in mice potentially could lead to a new approach for treating atherosclerosis in humans, according to researchers at Vanderbilt University Medical Center.

Lab manager Rachel Nargi prepares a B-cell culture during the recent “sprint” to develop an antibody-based treatment for Zika virus infection.

Study identifies antibodies that block alphaviruses

Researchers at Vanderbilt University Medical Center have identified antibodies that, in animals, block infection by alphaviruses, which can cause chronic and debilitating joint pain and arthritis and are an increasing global health concern.

A step toward cancer prevention

A computational technique that combines the effect of multiple genomic variants has the potential to identify high-risk individuals for cancer prevention.

Protein study may be key to treating fibrotic diseases

A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently.

(iStock)

VUMC’s program to repurpose drugs lands international acclaim

Vanderbilt University Medical Center is attracting international attention for its proposal to repurpose existing drugs for new uses in ways that can dramatically improve access to medicines by billions of people throughout the world.

Rice named to new leadership role for VICTR operations

Todd Rice, MD, MSc, has been appointed vice president for Clinical Trial Innovation and Operations in the Vanderbilt Institute for Clinical and Translational Research (VICTR).

1 32 33 34 35 36 110